ライフサイエンスコーパス: podoplanin

1 uronan (HA) receptor, is a novel partner for podoplanin.

2 cific CD44 antibody induced corecruitment of podoplanin.

3 hodocytin and the tumor cell surface protein podoplanin.

4 termined by immunohistochemical staining for podoplanin.

5 elial growth factor receptor 3 (VEGFR-3) and podoplanin.

6 of lymphatic endothelium such as LYVE-1 and podoplanin.

7 34, VE-cadherin, CD51/61, CD105, LYVE-1, and podoplanin.

8 en isolated via FACS-sorting with LYVE-1 and PODOPLANIN.

9 tified by staining immunohistochemically for podoplanin.

10 platelets promotes clustering of CLEC-2 and Podoplanin.

11 alitogenic molecular players like GM-CSF and podoplanin.

12 fty-one tumor specimens stained positive for podoplanin (33 high expression, 47 medium expression, 71

13 Levels of podoplanin (a marker of lymphatic vessels), VEGFC, and V

14 eficiency in CLEC-2 as well as inhibition of podoplanin, a ligand of CLEC-2, was associated with redu

15 We have shown that podoplanin, a lymphatic endothelial marker, is highly ex

16 We hypothesized that podoplanin, a sialomucin-like glycoprotein, increases th

17 Here, we uncover a new role for podoplanin, a transmembrane glycoprotein closely associa

18 Mesothelial cells expressed podoplanin and ALCAM.

19 al role in vascular inflammation through the podoplanin and collagen/fibrin receptors, C-type-lectin-

20 galectin-8-dependent crosstalk among VEGF-C, podoplanin and integrin pathways plays a key role.

21 Immunohistochemical staining against podoplanin and intratumoral platelet aggregates was perf

22 on of the lymphatic endothelial cell markers podoplanin and lymphatic vessel endothelial hyaluronan r

23 t Ebp1 has a key role in the upregulation of podoplanin and may contribute to oral tumorigenesis.

24 llows local inflammation and upregulation of podoplanin and platelet activation.

25 which CLEC-2 signaling promotes adhesion to Podoplanin and regulation of Podoplanin signaling, there

26 tent induction of the lymphatic marker genes podoplanin and vascular endothelial growth factor recept

27 The LYVE-1(-) lymphatic gaps expressed podoplanin and VE-cadherin but not alphaSMA or FOXC2.

28 n atypical phenotype, with the expression of podoplanin and VEGF receptor 3 (VEGFR-3) but not of LYVE

29 of systemic sclerosis patients, and CD34(-), podoplanin(+), and CD90(+) fibroblasts appear.

30 express surfactant proteins, ABCA3, GM-CSF, podoplanin, and caveolin mRNA after 7 days, temporal ind

31 receptor, C-type lectin 2, the receptor for podoplanin, and Fc receptor gammaII A, a low-affinity re

32 , semaphorin 3F, neuropilin 1, neuropilin 2, podoplanin, and LYVE-1 by quantitative (real-time) rever

33 ndothelial cell marker, Flt4/VEGFR3, but not podoplanin, and they have hyaluronan-binding ability.

34 antly patterned at embryonic (E) day 10.5 in podoplanin- and CLEC-2-deficient mice, preceding the for

35 othelial hyaluronate receptor 1 (LYVE-1) and podoplanin antibodies.

36 confirmed in normal mouse tissues with anti-podoplanin antibody 8.1.1.

37 esults also suggest the potential utility of podoplanin as a mechanism-based biomarker for rapid scre

38 We report podoplanin as a novel component of invadopodia-associate

39 These data identify T1alpha/podoplanin as a novel critical player that regulates dif

40 els was analyzed immunohistochemically using podoplanin as a specific lymphatic endothelial marker in

41 he multivariate analysis using histology and podoplanin as cofactors, podoplanin was the only indepen

42 e expression of lymphatic markers Prox-1 and podoplanin as early as 8 h p.i., and a paracrine effect

43 entify lymphatic vessels by using LYVE-1 and podoplanin as specific markers for lymphatic vascular en

44 antibody D2-40 specifically recognized human podoplanin, as assessed by enzyme-linked immunosorbent a

45 To induce deletion of podoplanin at the 2-cell stage, we generated a podoplani

46 We show that previously reported podoplanin-based LEC heterogeneity is associated with di

47 ated by its only known physiological ligand, podoplanin, being an integral membrane protein.

48 ligand by lymphoid tissue inducer cells and podoplanin by T zone stroma are temporally linked, and t

49 arrow, by a population of IL-17RA-expressing podoplanin(+)CD31(-) stromal cells, a profile associated

50 Podoplanin-CD44s interaction was demonstrated both by co

51 Podoplanin(+) cells also expressed high levels of lympha

52 We further confirmed that podoplanin(+) cells exist in small numbers in BM and per

53 Next, to evaluate the potential of podoplanin(+) cells for the formation of new lymphatic v

54 These podoplanin(+) cells highly express markers for lymphatic

55 ture-isolated or freshly isolated BM-derived podoplanin(+) cells into wound and tumor models.

56 Among these cells, podoplanin(+) cells were isolated by magnetic-activated

57 provide compelling evidence that BM-derived podoplanin(+) cells, a previously unrecognized cell type

58 These hPSC-derived LYVE-1(+)PODOPLANIN(+)cells showed a pure committed LEC phenotype

59 We suggest podoplanin-CLEC-2 as a novel anti-inflammatory axis regu

60 In carcinoma cells, CD44 and podoplanin colocalize at cell surface protrusions.

61 scular endothelium hyaluronate receptor) and podoplanin contribute to lymphatic vessels in full-thick

62 the presence of lymphatic endothelium using podoplanin (D2-40 antibody) and blood vessel endothelium

63 d in tumor-associated lymphangiogenesis, and podoplanin deficiency results in congenital lymphedema a

64 ly reduced in EHC T-syn(-/-) lymphatics, and podoplanin-deficient mice developed blood-filled lymphat

65 Podoplanin downregulation in SCC cells impairs invadopod

66 rdinately up-regulated together with that of podoplanin during progression to highly aggressive SCCs

67 tin-like receptor-2 (CLEC-2) on platelets by podoplanin exposed to the vasculature following breachin

68 CLEC-2 receptors by the transmembrane ligand podoplanin expressed by lymphatic endothelial cells.

69 for podoplanin or molecules associated with podoplanin expressing stroma in the effective segregatio

70 ciency is associated with reduced numbers of podoplanin-expressing macrophages despite increased cyto

71 on, IFN-gamma release enhanced the number of podoplanin-expressing monocytes and Kupffer cells in the

72 lar helper (Tfh) cell lineages, and included podoplanin-expressing T cells within lymphoid aggregates

73 lp areas, where they associate directly with podoplanin-expressing T zone stromal cells.

74 IL-27 inhibited the differentiation of podoplanin-expressing Th17 cells, and an increased numbe

75 In a high-density culture condition, podoplanin expression can be triggered at both mRNA and

76 terfering RNA-mediated inhibition of T1alpha/podoplanin expression decreased lymphatic endothelial ce

77 In conclusion, high podoplanin expression in primary brain tumors induces pl

78 -six (37%) of the 150 OPL patients exhibited podoplanin expression in the basal and suprabasal layers

79 erve as a transcriptional activator to drive podoplanin expression in the malignant progression.

80 m of DVT, whereby CLEC-2 and upregulation of podoplanin expression in the venous wall trigger thrombu

81 Podoplanin expression is associated with VTE in patients

82 Ebp1 downregulation significantly reduced podoplanin expression levels in OSCC cells with a decrea

83 However, mechanisms regulating podoplanin expression remain elusive.

84 High podoplanin expression was associated with an increased r

85 Podoplanin expression was determined in 150 OPL patients

86 postnatal development, in part by regulating podoplanin expression.

87 it led to significant decreases in IL-6 and Podoplanin expression.

88 sed risk of VTE (hazard ratio for high vs no podoplanin expression: 5.71; 95% confidence interval, 1.

89 We generated a human podoplanin-Fc fusion protein and found that the commerci

90 doplanin at the 2-cell stage, we generated a podoplanin(fl/fl) mouse crossed to a PGK-Cre mouse.

91 outinely used lymphatic endothelial marker), podoplanin, Flt4/VEGFR3, Sca-1, CD11b, or F4/80 and were

92 sion of another lymphatic-specific gene, the podoplanin gene, but does inhibit the expression of VEGF

93 Poorly studied podoplanin (gp38)-negative CD31(-) LNSCs showed similari

94 Thus, podoplanin has a key role in the regulation of invadopod

95 , research into the biological importance of podoplanin has been hampered by the lack of a generally

96 rotein rhodocytin and the endogenous protein podoplanin have been identified as ligands.

97 ased lymphatic vessel density as measured by podoplanin immunohistochemistry (P < 0.001) and whole mo

98 and lymphatic vessel density as measured by podoplanin immunohistochemistry and whole mount skin ana

99 and type I cells and/or type I cell-specific podoplanin immunoreactivity.

100 ng the functional role of CAF-like cells and podoplanin in CNT tumorigenic process.

101 pose of this study is to determine a role of podoplanin in predicting oral cancer development in pati

102 , primary dermal fibroblasts readily express podoplanin in response to the inflammatory stimuli tumor

103 The level of podoplanin in the IVC increased after 48 hours of stenos

104 These findings suggest a potential role of podoplanin in tumor progression, and they also identify

105 this study, we examined the role of T1alpha/podoplanin in vascular development and the effects of ge

106 f CLEC-2, a natural ligand/receptor for Gp38/Podoplanin, in the formation of the lymphatic vasculatur

107 stratified by considering both histology and podoplanin information.

108 Our results support a role for CD44-podoplanin interaction in driving tumor cell migration d

109 Podoplanin is a transmembrane glycoprotein up-regulated

110 T1alpha/podoplanin is also expressed in the basal epidermis of n

111 T1alpha/podoplanin is first expressed at around E11.0 in Prox1-p

112 Podoplanin is frequently expressed in OPL.

113 Podoplanin is highly expressed in human cancers.

114 ucin-type transmembrane glycoprotein T1alpha/podoplanin is predominantly expressed by lymphatic endot

115 The mucin-type glycoprotein podoplanin is specifically expressed by lymphatic but no

116 The presence of intraocular LYVE-1(+)/podoplanin(+) lymphatic vessels was significantly associ

117 Intraocular LYVE-1(+) and podoplanin(+) lymphatic vessels were detected in 7 of 10

118 ension revealed no intraocular LYVE-1(+) and podoplanin(+) lymphatic vessels.

119 for vascular and lymphatic markers including podoplanin, lymphatic vessel endothelial hyaluronan rece

120 ression of lymphatic markers such as Prox-1, podoplanin, Lyve-1, VEGF receptor-2, and VEGF receptor-3

121 elial cells based upon reduced expression of podoplanin, LYVE1 and VEGFR3.

122 Together with histology, podoplanin may serve as a powerful biomarker to predict

123 T1alpha/podoplanin(-/-) mice die at birth due to respiratory fai

124 Clusters of CLEC-2-bound Podoplanin migrate rapidly to the center of the platelet

125 , they begin expressing the lymphatic marker podoplanin, migrate away from the CV, and form the lymph

126 othelial hyaluronan receptor-1 (LYVE-1), and podoplanin mRNA and contained more lymphatic vessels tha

127 promoter to result in a dramatic increase of podoplanin mRNA and protein.

128 of oral cancer than did those whose OPL was podoplanin negative (P = .0002).

129 Treatment of animals with an anti-podoplanin neutralizing antibody resulted in development

130 own experiments showed that an expression of podoplanin on CAF-like cells is essential for their effe

131 lectin receptor 2 (CLEC-2) on platelets with Podoplanin on lymphatic endothelial cells initiates plat

132 Nestin-Cre-driven deletion of podoplanin on neural progenitors also caused widespread

133 od, Tamura et al reveal a novel function for podoplanin on periarteriolar stromal cells in the bone m

134 Finally, we show that the appearance of podoplanin on T zone stroma in development is associated

135 up-regulate the expression of both CCL21 and podoplanin on T zone stroma of RAG-deficient mice.

136 Abs of the transmembrane mucin-type protein podoplanin on T zone stroma, although expression at othe

137 We propose a novel role for podoplanin on the neuro-epithelium, which interacts with

138 e not all lymphatic progenitor cells express podoplanin or Lyve-1, which are acquired with advancing

139 and our data point to a significant role for podoplanin or molecules associated with podoplanin expre

140 imbalances, polysomy, p53, overexpression of podoplanin, p63 or epidermal growth factor receptor (EGF

141 17 (IL-17) and on the cell surface molecule Podoplanin (Pdp), which was expressed on Th17 cells, but

142 report here that Src utilizes Cas to induce podoplanin (Pdpn) expression to promote tumor cell migra

143 ion tissue or fluid on the basis of CD31 and podoplanin (PDPN) expression.

144 Podoplanin (Pdpn) is a small, transmembrane glycoprotein

145 Podoplanin (PDPN) is a transmembrane receptor that affec

146 Here we demonstrate that podoplanin (PDPN) regulates actomyosin contractility in

147 city of lymph nodes is maintained in part by podoplanin (PDPN) signalling in stromal fibroblastic ret

148 PODOPLANIN (PDPN), a transmembrane protein expressed on

149 hibitor of metalloproteinases 1 (Timp1), and podoplanin (Pdpn), were significantly FGF-2 dependent fo

150 omal scaffolds that display the glycoprotein podoplanin (PDPN).

151 r cells mediated cell survival by modulating podoplanin (PDPN).

152 a role for the transmembrane O-glycoprotein podoplanin (PDPN, also known as gp38 and T1alpha) in mai

153 Podoplanin (PDPN, also known as Gp38) is highly expresse

154 Patients with OPL that was podoplanin positive had significantly higher incidence o

155 and suprabasal layers and were classified as podoplanin positive.

156 es the differentiation of lung stroma toward podoplanin-positive CXCL12-expressing cells that allow f

157 CAS more than 4, as well as rare staining of podoplanin-positive lymphatic vessels within acutely inf

158 Podoplanin-positive primary glioblastoma cells induced a

159 Patients with podoplanin-positive tumors had lower peripheral blood pl

160 Podoplanin positivity was more frequent in older patient

161 he cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of

162 ured endothelial cells indicate that T1alpha/podoplanin promotes cell adhesion, migration and tube fo

163 Importantly, we also show that podoplanin promotes directional persistence of motility

164 Here we show that podoplanin promotes tumorigenesis of oral squamous cell

165 st of the OSCC cell lines have no detectable podoplanin protein in low-density cultures.

166 21 mice promoted the development of LYVE-1(+)podoplanin(+)Prox-1(+) vessels in the thyroid.

167 collagen receptor glycoprotein VI (GPVI) and podoplanin receptor C-type lectin-like receptor 2 (CLEC2

168 Early podoplanin recruitment to invadopodia is dependent on li

169 bition of the interaction between CLEC-2 and podoplanin regulates immune cell infiltration and the in

170 Finally, we demonstrate that podoplanin regulates invadopodia maturation by acting up

171 rafts, whereas ezrin/moesin proteins mediate podoplanin ring assembly.

172 tes adhesion to Podoplanin and regulation of Podoplanin signaling, thereby contributing to lymphatic

173 Podoplanin staining intensity was associated with increa

174 Furthermore, podoplanin staining on stromal cells was more diffuse, a

175 Immunofluorescence indicated that podoplanin(+) stromal cells in the red pulp were the pri

176 vasculature and the differentiation of Gp38/Podoplanin(+) stromal cells, we investigated the role of

177 vascular marker, CD31, and lymphatic marker, podoplanin, suggesting a role for macrophages in angioge

178 during sepsis, suggesting that activation of podoplanin underlies the anti-inflammatory action of pla

179 on enhanced these malignant features through podoplanin upregulation both in vitro and in vivo.

180 iferating lymphatic vessels, with LYVE-1 and podoplanin used as specific lymphatic endothelial marker

181 lso seen in platelets adhered to immobilized Podoplanin using direct stochastic optical reconstructio

182 embranes from patients did not show LYVE-1(+)podoplanin(+) vessels, suggesting the lack of lymphangio

183 that, in addition to lymphatic endothelium, podoplanin was also expressed by peritoneal mesothelial

184 Podoplanin was also strongly expressed by granulosa cell

185 Podoplanin was expressed in the IVC wall, where it was l

186 Although podoplanin was primarily absent from normal human epider

187 The level of O-glycoprotein podoplanin was significantly reduced in EHC T-syn(-/-) l

188 using histology and podoplanin as cofactors, podoplanin was the only independent factor for oral canc

189 g supported lipid bilayers containing mobile Podoplanin, we further show that activation of Src and S

190 he GPVI ligand collagen and the CLEC2 ligand podoplanin were constitutively present in the lung, wher

191 CLEC-2 activation by its endogenous ligand, podoplanin, which is expressed on the developing neural